Acadia Pharmaceuticals ACAD Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.1B+9.9% | $1.07B+11.9% | $1.05B+12.7% | $1.02B+14.4% | $996.28M+22.4% | ||
| $93.4M+17.8% | $89M+8.7% | $84.58M+8.5% | $81.79M+11.0% | $79.28M+26.0% | ||
| $1B+9.3% | $982.51M+12.2% | $962.54M+13.1% | $937.1M+14.7% | $917M+22.1% | ||
| 91.5%-0.6pp | 91.7%+0.2pp | 91.9%+0.3pp | 92%+0.2pp | 92%-0.2pp | ||
| $327.41M+1.7% | $328.8M+8.4% | $344.78M+28.0% | $323.55M-10.0% | $321.84M-5.9% | ||
| $593.54M+17.1% | $548.89M+12.4% | $523.36M+11.4% | $523.25M+20.5% | $506.81M+22.6% | ||
| $1.01B+33.2% | $966.69M+33.0% | $806.2M-1.3% | $782.08M-9.9% | $761.41M-7.0% | ||
| $80.91M-65.6% | $104.81M-54.6% | $240.92M— | $236.81M— | $234.87M— | ||
| 7.4%-16.2pp | 9.8%-14.3pp | 23%— | 23.2%— | 23.6%— | ||
| $31.88M+14.4% | $31.72M+24.6% | $30.4M+31.0% | $28.74M+38.5% | $27.85M+47.1% | ||
| $2.33M+9.4% | $2.37M+30.1% | $2.35M+88.3% | $2.33M+7.0% | $2.13M+286% | ||
| —— | $0-100% | $36.63M-66.7% | $73.26M0.0% | $109.89M+200% | ||
| $115.11M-56.5% | $138.9M-46.2% | $273.67M— | $267.88M— | $264.85M— | ||
| -$260.54M-824% | -$252.1M-897% | $12.5M— | $45.72M— | $35.97M— | ||
| $375.65M+64.1% | $391M+72.7% | $261.17M+103% | $222.16M+627% | $228.88M+13,485% | ||
| 34.3%+11.3pp | 36.5%+12.8pp | 24.9%+11.1pp | 21.8%+18.4pp | 23%+23.2pp | ||
| $2.21+61.3% | $2.30+69.1% | $1.55+98.7% | $1.33+639% | $1.37+13,800% | ||
| $2.23+61.6% | $2.32+69.3% | $1.57+101% | $1.34+644% | $1.38+13,900% | ||
| 682M+2.3% | 676.9M+1.7% | 673.4M+1.6% | 668.9M+1.2% | 666.4M+1.0% | ||
| 675.5M+1.7% | 671.8M+1.5% | 669.2M+1.4% | 666.3M+1.2% | 664.1M+1.2% | ||
| $31.88M+14.4% | $31.72M+24.6% | $30.4M+31.0% | $28.74M+38.5% | $27.85M+47.1% | ||
| $913K+0.7% | $871K-5.3% | $895K-7.3% | $894K-18.7% | $907K-28.9% | ||
| —— | $25.17M+28.9% | $23.76M+47.5% | $22.35M+76.1% | $20.93M+126% | ||
| -$5.85M-373% | -$5.29M-291% | $2.67M-60.6% | $215K-79.9% | -$1.24M-165% | ||
| $4.41M-92.5% | -$19.27M-127% | $79.9M+1.9% | $65.37M-30.0% | $58.75M-27.3% | ||
| $2.3M+392% | $2.86M+2,541% | $2.01M+1,829% | $1.19M— | $468K— | ||
| -$7.33M-184% | $1.08M-62.8% | -$1.43M-154% | $16.19M+421% | $8.69M+45.6% | ||
| $2.33M+9.4% | $2.37M+30.1% | $2.35M+88.3% | $2.33M+7.0% | $2.13M+286% | ||
| $9.9M— | $4.69M— | $1.14M— | $820K— | —— | ||
| $52.28M+584% | $49.88M+629% | $29.19M+183% | $20.03M-12.1% | $7.64M-69.1% | ||
| $449.23M+14.2% | $493.53M+50.2% | $499.63M+55.9% | $443.14M+42.7% | $393.25M+66.3% | ||
| $1.1B+9.9% | $1.07B+11.9% | $1.05B+12.7% | $1.02B+14.4% | $996.28M+22.4% | ||
| $55.45M-12.9% | $52.14M-22.2% | $49.35M-33.9% | $62.33M-7.0% | $63.68M-4.2% | ||
| $80.91M-65.6% | $104.81M-54.6% | $240.92M— | $236.81M— | $234.87M— | ||
| $92.71M-62.6% | $116.57M-52.7% | $254.97M— | $250.48M— | $248.18M— | ||
| $92.71M-62.6% | $116.57M-52.7% | $254.97M— | $250.48M— | $248.18M— | ||
| 8.5%-16.4pp | 10.9%-14.9pp | 24.3%— | 24.6%— | 24.9%— | ||
| $80.91M-65.6% | $104.81M-54.6% | $240.92M— | $236.81M— | $234.87M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Acadia Pharmaceuticals's profit margins?
- Gross margin is 91.5% and operating margin is 7.4%, with a 34.3% net margin.
- Where does Acadia Pharmaceuticals's income statement data come from?
- Every line is extracted from Acadia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.